Inhibition of dipeptidyl peptidase 4 (DPP4), a regulator of glucose metabolism (Mourad et al., 2021), showed protective effects in several inflammatory conditions, including cardiovascular diseases, renal disorders, liver diseases, multiple sclerosis, and IBDs (Seong et al., 2019; Ning et al., 2020; Daza-Arnedo et al., 2021; Chen et al., 2022; Sharma et al., 2022). Here, DPP4 is linked to multiple sclerosis.